{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.3","upperLimit":"95.7","value":"66.7"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"98.7","value":"50.0"},{"groupId":"OG003","lowerLimit":"10.9","upperLimit":"69.2","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"description":"ORR was evaluated for each of Cohort 4 sub-cohorts: 4A (primary mediastinal B-cell lymphoma), 4B (grey zone, splenic marginal zone, and mantle cell lymphomas), 4C (follicular lymphoma), and 4D (diffuse large B-Cell lymphoma). ORR was defined as the percentage of participants with response (complete response \\[CR\\] or partial response \\[PR\\]) according to revised response criteria for malignant lymphoma per Cheson et al. 2007. CR was demonstrated by disappearance of all evidence of disease in bone marrow, spleen, liver, and lymph nodes. PR was \\>50% decrease in the sum of product diameters (SPD) for ≤6 target masses for lymph nodes and \\>50% decrease in SPD for a single nodule in greatest transverse diameter for spleen and liver, and no size increase in the lymph nodes, spleen, or liver. PD-L1 was assessed by immunohistochemistry (IHC). The percentage of participants with CR and PR as assessed by the investigator is presented for participants with an indeterminate (missing) PD-L1 status.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)"},{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG001","title":"Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"Cohort 4C: R/R Follicular Lymphoma (FL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)"}],"paramType":"NUMBER","populationDescription":"All participants in Cohorts 4A, 4B, 4C, and 4D, who had an indeterminate PD-L1 status, with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation. ORR was not analyzed for Cohort 4B because there were no participants with a PD-L1 status of indeterminate in this Cohort.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants in the Cohort 4 Non-Hodgkin Lymphoma (NHL) Individual Sub-Cohorts (Cohorts 4A, 4B, 4C, and 4D)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}